Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays

Abstract

Circulating tumor DNA (ctDNA) has emerged as a non-invasive diagnostic and prognostic tool for colorectal cancer (CRC). Here, we discuss studies that evaluate the ability of plasma-only ctDNA assays to detect minimal residual disease (MRD) and the potential benefit of integration of methylation into ctDNA assays.